The first approved treatment for primary progressive multiple sclerosis, ocrelizumab, targets this antigen. For 10 points each:
[10m] Name this antigen found on the surface of B cells. This antigen is targeted by the first antibody approved for cancer patients, rituximab.
ANSWER: CD20 [accept MS4A1]
[10h] In addition to attracting NK cells in antibody-dependent cellular cytotoxicity, rituximab also induces complement-dependent cytotoxicity. This protein complex binds to antibody-antigen complexes in the classical complement pathway.
ANSWER: C1 [or complement component 1; accept C1q or complement component 1q]
[10e] The suffix “-mab” in rituximab and ocrelizumab refers to them being medicines composed of these antibodies. Fused hybridomas produce these antibodies which target a single epitope.
ANSWER: monoclonal antibodies [or mAb]
<Science - Biology>